Multivariate analyses revealed that TRIM21 is an independent indicator for OS of patients with glioma (Figure S1E), Relative to gliomas in the TRIM21 Low group, gliomas with high expression of the TRIM21 exhibited more GBM and Chr.7.gain/Chr.10.loss, fewer IDH mutations, ATRX mutation, MGMT methylation, and 1p/19q co-deletion (Figure 1I and Table 1). The gene discussed is ATRX; the disease is central nervous system cancer.